Tretinoin for Hair Loss: Does It Work Without Minoxidil?
Published by AmpleLab Research
Tretinoin comes up constantly in hair loss discussions, almost always attached to minoxidil. The standard claim is that tretinoin helps minoxidil work better by improving how much of it actually gets absorbed. A separate, less consistent claim also circulates: that tretinoin does something for hair on its own, independent of minoxidil entirely. These two claims get treated as though they're the same idea told two ways. They aren't. They rest on different studies, different mechanisms, and a body of evidence that points in more than one direction.
This article separates the two questions. First, what tretinoin does to minoxidil absorption, and which mechanism is actually responsible for that. Second, what evidence exists for tretinoin having an effect on hair growth by itself, including a 2005 human tissue study that found the opposite of what standalone-benefit claims assume. The short version: both claims have real evidence behind them, both are weaker or narrower than they're usually presented, and there's an underdiscussed body of research suggesting tretinoin can push hair follicles in the wrong direction under some conditions.
The Absorption Claim, and the Mechanism Behind It
The absorption-enhancement claim traces to a specific, controlled human study from 1990, and it holds up reasonably well. What gets misstated online is the mechanism behind it.
Nineteen healthy male volunteers completed a randomised, three-way crossover study over 20 days, applying 2% topical minoxidil twice daily either alone, alongside once-daily 0.05% tretinoin cream, or alongside a vehicle control cream. Minoxidil absorption increased nearly threefold when co-administered with tretinoin, compared with a 1.3-fold increase from the vehicle control alone. Transepidermal water loss, a marker of stratum corneum barrier function, rose significantly with tretinoin. Skin biopsy showed no measurable change in stratum corneum thickness. The researchers' own conclusion attributes the effect to increased stratum corneum permeability, not to any change in minoxidil's metabolism or activation.
That last point matters, because a different, unrelated mechanism gets confused with this one constantly online: minoxidil sulfotransferase. Minoxidil is a prodrug. It has to be converted into minoxidil sulfate by a follicular enzyme, SULT1A1, before it does anything to hair follicles, and people with lower SULT1A1 activity respond less well to topical minoxidil. This is a real, separate, well-documented mechanism, and it has nothing to do with the permeability effect Ferry and colleagues measured. Content describing tretinoin's absorption benefit as working "by boosting minoxidil sulfotransferase" is describing the wrong mechanism for the wrong study. The 1990 finding is a skin-barrier effect. The enzyme story is a different, smaller body of research, covered next.
A Second, Separate Mechanism: Sulfotransferase Activity
A smaller 2019 study looked at whether tretinoin affects SULT1A1 activity directly, rather than skin permeability. It found a measurable effect, though the study's size and funding source are worth knowing before weighing it.
Twenty subjects (ten male, ten female) with androgenetic alopecia were tested for follicular sulfotransferase activity, then treated with five days of 0.1% topical tretinoin and retested. Among participants who had initially tested as predicted minoxidil non-responders, mean enzyme activity rose from 0.26 to 0.35 OD 405nm after five days of tretinoin, a statistically significant but modest increase (p=0.0397, one-sided test). Forty-three percent of predicted non-responders shifted into the predicted-responder range. Several authors, including the study's corresponding author, are affiliated with Applied Biology, the company that commercialises the minoxidil-response test used to classify subjects in this study.
Worth being precise about what this does and doesn't show. This is a statistically significant shift in a specific biomarker (p=0.0397, one-sided test), in a small sample, run by researchers with a commercial stake in the test used to classify subjects. It measured enzyme activity and predicted response category, not actual hair regrowth. Some content elsewhere reports this study with inflated figures, a "1.8-fold" SULT1A1 increase that doesn't match the primary numbers Sharma and colleagues themselves reported. Those primary numbers are worth citing on their own terms rather than rounded up.
Where the "Tretinoin Works Alone" Claim Comes From
Much of the online claim that tretinoin promotes hair growth by itself traces back to one 1986 case series. That study is foundational to the whole conversation, and it is considerably weaker evidence than the confidence it gets cited with would suggest.
Fifty-six subjects with androgenetic alopecia used either topical tretinoin alone or tretinoin combined with 0.5% minoxidil for up to a year. Tretinoin alone produced some regrowth in approximately 58% of subjects. The combination produced terminal hair regrowth in 66%. There was no placebo-controlled arm or blinded assessment, only a comparison between tretinoin alone and tretinoin plus minoxidil. Response was assessed by the investigators' own photographic and clinical judgement. This design can generate a hypothesis worth testing further. It cannot, on its own, establish that tretinoin caused the regrowth observed, given the well-documented tendency for open-label hair loss studies to show improvement from expectation and assessment bias alone.
For nearly four decades, that remained the main clinical evidence cited for tretinoin having a standalone effect on hair growth. A far stronger, more mechanistically grounded study only arrived in 2025.
This study identified retinoic acid signalling as suppressed in miniaturised follicles from androgenetic alopecia patients, and showed retinoic acid activates hair follicle stem cells by driving the telogen-to-anagen transition through Wnt/β-catenin signalling, a defined stem cell pathway rather than a generic proliferation effect. The clinical arm compared 30 patients using 0.025% topical tretinoin against 30 using 5% minoxidil, tracking hair count, hair diameter, and terminal hair ratio at one, three, and six months. The tretinoin group improved significantly from baseline at one month (p<0.001) in hair count, density, and diameter. By six months, anagen hair ratio had increased further, but showed no significant difference from the minoxidil group. This is a small, active-comparator clinical study, not a placebo-controlled trial demonstrating tretinoin outperforms minoxidil, paired with tissue-level and mechanistic experiments identifying a specific pathway. That combination is a stronger foundation than the 1986 case series, even without a superiority result at six months.
The Study Most "Tretinoin Grows Hair" Content Leaves Out
A controlled human tissue study found tretinoin doing the opposite of stimulating growth, and it rarely gets mentioned alongside the standalone-benefit claim.
Human scalp hair follicles in the active growth (anagen) phase were cultured with all-trans retinoic acid, tretinoin's active form, at two concentrations. Hair shaft elongation declined within two days. By day six, around 80% of treated follicles had entered a catagen-like regression stage, versus 30% of untreated controls, with a corresponding rise in apoptotic cells and fall in proliferating cells. The mechanism identified was upregulation of TGF-β2 in the dermal papilla, a signalling molecule with an established role as a catagen inducer; a neutralising antibody against TGF-β2 partially blocked the growth-inhibiting effect, supporting that pathway as causal rather than coincidental.
This finding lines up with something already well established clinically: systemic retinoids, isotretinoin and acitretin in particular, are a recognised cause of diffuse hair shedding as a side effect. Foitzik and colleagues' catagen-induction mechanism gives that clinical phenomenon a plausible cellular explanation. This is a controlled, mechanistic, human tissue study, a stronger evidentiary tier than the open-label case series behind the standalone-benefit claim, and it points in the opposite direction.
None of this cancels out the Wen 2025 findings above. Ex vivo organ culture at fixed concentrations and a clinical trial using a cosmetic-strength formulation over months are different experimental conditions, and concentration, formulation, and duration plausibly determine which effect dominates. What it does mean is that "tretinoin stimulates hair growth" isn't a settled fact with only supportive evidence behind it. It remains a live, contested question, and any complete answer has to account for a study showing the opposite result under controlled conditions.
What the Controlled Combination Trials Found
Two randomised trials tested minoxidil-plus-tretinoin against minoxidil alone directly. Neither found the combination clearly superior.
A 2007 randomised, double-blind trial in 31 men compared 5% minoxidil applied twice daily against a combined solution of 5% minoxidil and 0.01% tretinoin applied once daily. Both groups showed increases in total hair count and non-vellus hair count, with no statistically significant difference between them in any macrophotographic measure or in subjective global assessment by patients or investigators. The trial's framing was not that tretinoin improves on minoxidil, but that once-daily combined therapy could match twice-daily minoxidil alone, a convenience finding rather than an efficacy finding.
A separate randomised, double-blind trial in 117 men compared a lower-dose combination, 0.5% minoxidil plus 0.05% tretinoin, against 2% minoxidil alone over four months. Again, no statistically significant difference emerged between groups in reported improvement, hair regrowth, or wash-test hair counts. Across both trials, adding tretinoin allowed a lower minoxidil dose or a more convenient dosing schedule to perform comparably to standard-dose minoxidil alone. Neither trial demonstrated the combination outperforming minoxidil on its own.
Where This Leaves the Two Original Claims
The claim that tretinoin increases minoxidil absorption holds up under controlled testing. Tretinoin measurably increases minoxidil absorption, through a skin-barrier permeability effect rather than the sulfotransferase mechanism often credited for it, and a separate, smaller line of research suggests a modest, industry-funded finding on enzyme activity that hasn't been independently replicated at scale. Neither mechanism has translated into a clearly superior outcome over minoxidil alone in the two controlled trials that tested combination therapy head-to-head; what they've shown is comparable results at a lower dose or a more convenient schedule.
The standalone claim rests on an unresolved mechanistic tension rather than a settled answer. A 1986 open-label case series without a placebo-controlled arm remains the most-cited evidence for it, and a considerably stronger 2025 study has since identified a specific stem cell pathway retinoic acid appears to activate in balding follicles, alongside a small active-comparator clinical trial that showed early improvement but no six-month advantage over minoxidil. Set against both is a controlled 2005 human tissue study showing tretinoin inducing follicle regression through a different, well-characterised pathway, a finding consistent with the established clinical pattern of hair shedding from systemic retinoids. Formulation, concentration, and duration are the most plausible explanations for how both directions of evidence coexist, but nobody has directly tested that in a way that resolves it.
For anyone weighing where tretinoin fits in a broader protocol, this is also where a topical with a more consistently one-directional mechanism, rather than one with evidence pointing both ways, becomes a reasonable point of comparison. AHK-Cu against minoxidil covers how a copper peptide's mechanism compares on that front.
Frequently Asked Questions
Does tretinoin help minoxidil work better?
A controlled 1990 study found tretinoin increased minoxidil absorption nearly threefold by improving stratum corneum permeability. Despite that measured absorption increase, the two randomised trials that tested minoxidil-plus-tretinoin against minoxidil alone did not find the combination clearly outperforming minoxidil on its own; they found comparable results at a lower dose or more convenient schedule.
Does tretinoin boost minoxidil sulfotransferase?
That claim conflates two different studies. The main absorption effect (Ferry et al., 1990) works through skin permeability, not enzyme activity. A separate, smaller 2019 study did find tretinoin raised follicular sulfotransferase activity modestly in predicted minoxidil non-responders, but the effect size in that study is smaller than commonly reported, and the researchers involved have a commercial link to the response test used.
Can tretinoin regrow hair without minoxidil?
The evidence is mixed. A 1986 open-label case series with no placebo-controlled arm reported regrowth in 58% of subjects using tretinoin alone, and a stronger 2025 study identified a specific stem cell pathway retinoic acid activates in balding follicles, though its clinical arm showed no significant advantage over minoxidil by six months. Against that, a controlled 2005 human tissue study found tretinoin inducing follicle regression through a separate mechanism. Both directions have experimental evidence behind them: controlled human tissue evidence for the negative effect, and a small clinical study plus mechanistic evidence for the positive one.
Can tretinoin cause hair loss?
A 2005 human hair follicle study found retinoic acid, tretinoin's active form, pushed follicles into a regression phase within days through TGF-β2 signalling. This lines up with the well-documented pattern of diffuse shedding as a side effect of systemic retinoids like isotretinoin. Whether topical, cosmetic-strength tretinoin reaches enough of the scalp to trigger the same effect hasn't been directly tested.
Is combining minoxidil and tretinoin worth it?
The controlled trial evidence shows the combination performing comparably to minoxidil alone, sometimes at a lower minoxidil dose or a more convenient once-daily schedule, rather than outperforming it. Whether that trade-off is worthwhile depends on individual tolerance and response, and is a reasonable question to raise with a dermatologist given tretinoin's off-label status for this use.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. Tretinoin is a prescription medication used off-label for hair loss; consult a dermatologist before starting or combining it with other treatments. AmpleLab products are cosmetic formulations, unrelated to tretinoin, and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.